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Abstract: Diabetes mellitus (DM) markedly potentiates the risk of cardiovascular morbidity and mortality among indi-
viduals with diabetes as compared to the non-diabetic population. After myocardial infarction (MI), DM patients have a 
higher incidence of death than do non-diabetics. The excess mortality and poor prognosis of these patients results primar-
ily from the development of recurrent MI and heart failure (HF). Although several lines of evidence support a role for in-
creased oxidative stress in a range of cardiovascular diseases, clinical trials examining the therapeutic efficacy of antioxi-
dants have yielded conflicting results. The reasons for these incongruous results is multifactorial. An underlying theme 
has been lack of patient inclusion based on elevated indices of oxidative stress which could have diluted the population 
susceptible to benefit in the clinical trials. Laboratory evidence has accumulated indicating that oxidative stress is dra-
matically accentuated in cardiac abnormalities inherent in DM. In this review, we provide the emergence of experimental 
and clinical evidence supporting antioxidant supplementation as a cardioprotective intervention in the setting of DM. Spe-
cifically, focus will be directed on preclinical animal studies and human clinical trials that have tested the effect of anti-
oxidant supplements on MI and HF events in the presence of DM. 
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INTRODUCTION 
  An estimated 77% of U.S. hospitalizations for complica-
tions of diabetes mellitus (DM) are linked to cardiovascular 
disease [1]. Patients with DM have substantially higher car-
diovascular morbidity and mortality than their non-diabetic 
counterparts. According to a new study commissioned by the 
American Diabetes Association (ADA), 20.8 million chil-
dren and adults in the United States have DM, with 1.5 mil-
lion new cases of DM diagnosed annually (http://www.dia-
betes.org/diabetes-statistics/prevalence.jsp; accessed April, 
2008). A recent multinational study indicated that cardiovas-
cular disease was the most common underlying cause of 
death, accounting for 44% of deaths in type 1 (insulin-
dependent) DM and 52% of deaths in type 2 (non-insulin-
dependent) DM [2]. The reduced survival rate of patients 
with DM has been reported to result primarily from the more 
frequent development of heart failure (HF) and recurrent 
myocardial infarction (MI) [1, 3-9]. The combination of a 
specific diabetic cardiomyopathy and co-morbidities associ-
ated with DM (including obesity, dyslipidemia, hyperten-
sion, and coronary artery disease), independently and coop-
eratively, lead to structural and functional abnormalities of 
the heart culminating in cardiac dysfunction and ultimately 
HF [10, 11]. With the prevalence of DM rising and ap-
proaching pandemic proportions worldwide [12] due, in part, 
to rising rates of obesity and attendant metabolic syndrome 
(MS) [11], it is likely that the incidence of cardiovascular 
morbidity and mortality will continue to increase in this 
high-risk population. 
*Address correspondence to this author at the Department of Medicine, 
Division of Cardiovascular Medicine, Vanderbilt University Medical Cen-
ter, 2220 Pierce Avenue, Room #383, Preston Research Building, Nashville, 
TN 37232, USA; Tel: (615) 936-2412; Fax: (615) 936-1872;  
E-mail: michael.f.hill@vanderbilt.edu 
  Available evidence from experimental models as well as 
observational studies have reported that DM increases oxida-
tive stress and that the onset of DM and its cardiac complica-
tions, including diabetic cardiomyopathy, are closely associ-
ated with accentuated oxidative stress [13-18]. However, 
clinical trials examining the use of antioxidants specifically 
in patients with DM is limited. Although randomized pla-
cebo-controlled clinical trials evaluating the efficacy of anti-
oxidants in preventing cardiovascular events have yielded 
conflicting results [19-26], none of these studies used, as 
endpoints, biomarkers that were specific and sensitive for 
oxidative stress. Moreover, the ability of the antioxidants 
tested to reduce significantly the levels of oxidative stress in 
study participants in these trials was never determined. The 
absence of knowledge regarding the effects of antioxidants 
on specific markers of oxidative stress in these studies has 
rendered the lack of consistent cardiovascular benefit in 
these patients difficult to interpret and open to further inves-
tigation. In that regard, the emergence of a reliable and spe-
cific marker of oxidative stress status, i.e., measurement of 
F2-isoprostanes, has led to a burgeoning of experimental and 
clinical studies exploring the ability of antioxidants to miti-
gate cardiovascular disease in DM. The purpose of this re-
view is to highlight accumulating evidence in favor of anti-
oxidants to be used as prophylactic and therapeutic agents 
against MI and HF events in the setting of DM. 
OXIDATIVE STRESS 
  Oxidative stress is defined as an imbalance between the 
generation of free oxygen radicals (FORs) and the antioxi-
dant defense system. In the simplest of terms, a free radical 
is any atom or molecule that has an unpaired electron in their 
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species. Free radical production occurs via the addition of an 
electron or by its removal in a reduction/oxidation reaction. 
Due to its unique diradical configuration, oxygen is a major 
intracellular source of radical species. A sequential univalent 
reduction of oxygen gives rise to reactive intermediate prod-
ucts [27, 28]. A single electron reduction of oxygen gives 
rise to superoxide anion (O2
-), which can act as both a reduc-
ing and an oxidizing agent. The relatively short half life of 
superoxide anion limits its diffusion away from the site of its 
generation. The divalent reduction of oxygen yields the 
nonradical species, hydrogen peroxide (H2O2). H2O2 has a 
relatively long half life and therefore can travel significant 
distances, causing damage at sites distant from its origin. A 
three electron reduction of oxygen yields the hydroxyl radi-
cal (OH
-), which is the most reactive and potent of all the 
free oxygen radicals. Addition of a fourth electron results in 
the formation of water. All of these reactive oxygen interme-
diates are called activated oxygen species and are collec-
tively termed as partially reduced forms of oxygen (PRFO) 
[29]. Endogenous sources of free radicals are the numerous 
enzyme and non-enzyme systems located in the subcellular 
membranes, plasma membrane, and blood cell elements.  
ANTIOXIDANTS 
  Due to a continuous generation of PRFO during cardiac 
cell metabolism, a number of protective enzymatic as well as 
non-enzymatic antioxidants have evolved constituting an 
antioxidant reserve [29] that act to limit the tissue concentra-
tion of these highly reactive species. A proper balance be-
tween the generation of PRFO and the antioxidant defense 
system is critical for the maintenance of a normal myocardial 
cell structure and function.  
Enzymatic Antioxidants 
  Three of the most important enzymes commonly present 
in most cells are superoxide dismutase (SOD), catalase 
(CAT), and glutathione peroxidase (GSHPx). SOD catalyzes 
the dismutation of O2
- to H2O2. Both CAT and GSHPx cata-
lyze the reduction of H2O2 to water, thereby preventing the 
formation of the potent OH
-. A detailed account of these an-
tioxidant enzymes has been provided in several reviews [27, 
30, 31].  
Non-Enzymatic Antioxidants 
  The most important non-enzymatic antioxidants are vi-
tamin E, vitamin C and glutathione. Vitamin E is an impor-
tant micronutrient that also functions as an antioxidant. It 
acts to protect polyunsaturated fatty acids (PUFA) from oxi-
dation by interrupting the chain of membrane lipid peroxida-
tion and thus is also referred to as a “chain-breaking” anti-
oxidant [32]. Since vitamin E is lipid soluble, deficiency of 
myocardial vitamin E levels result in the increased suscepti-
bility of myocardial cell membranes to FOR mediated lipid 
peroxidation [33, 34]. Lipid peroxidation chain reaction in 
the membrane is “initiated” by the removal of hydrogen from 
the unsaturated site in a fatty acid resulting in the production 
of a lipid radical. The radical thus generated can interact with 
more PUFA and the chain is “propagated”. During this proc-
ess, the chroman head group of vitamin E encounters a lipid 
radical, resulting in the generation of a vitamin E radical.  
The vitamin E radical is much more sta-ble, and less reac-
tive, than the lipid radical. This effectively terminates lipid 
peroxide mediated chain reactions. The resultant vitamin E 
radical is incapable of any further free radical scavenging 
activity. Thus, it must be regenerated back to a functional 
vitamin E molecule. Vitamin C, present in the water phase, 
regenerates vitamin E to the reduced form and therefore acts 
to spare the functional form of vitamin E [27].  
  Glutathione is present in high concentrations as reduced 
(GSH) glutathione with minor fractions being oxidized 
(GSSG) glutathione [35]. GSH as a co-substrate of GSHPx, 
plays an important role in the removal of H2O2 as well as 
other organic peroxides, thus preventing the peroxidation of 
membrane lipids [36]. Study of changes in glutathione status 
provides important information on cellular oxidative events 
and tissue accumulation and/or release of GSSG.  
OXIDATIVE STRESS AND TISSUE INJURY 
  Under normal physiological conditions, the tissue con-
centration of FORs is limited due to the existence of a deli-
cate balance between the generation of PRFO and the anti-
oxidant defense system [37]. However, if this balance is dis-
turbed in favor of more PRFO, either through an enhanced 
production or via a reduction in the endogenous antioxidant 
defense system or both, the heart is at risk for PRFO-
mediated myocardial cell damage. Thus, changes in myocar-
dial antioxidant status and oxidative stress may have pro-
found effects on cardiac structure and function [38].  
  One mechanism of tissue damage induced by PRFO is 
via lipid peroxidation, in which there is formation of lipid 
peroxides within myocardial cell membranes. This process is 
initiated when one hydrogen is abstracted from PUFA by a 
free radical to form fatty acid radicals [27]. In addition, 
PRFO can cause oxidation of the thiol groups in proteins and 
can directly interact with nucleic acids. Thus, in these 
chemical reactions, there are structural as well as functional 
modifications in the macromolecules leading to modifica-
tions/alterations in cell and organ function.  
OXIDATIVE STRESS IN DM AND CARDIOVASCU-
LAR DISEASE 
Experimental Studies 
  DM is characterized by a variety of metabolic abnormali-
ties, principal among which are hypoinsulinemia (type 1 
DM), insulin resistance (type 2 DM), and hyperglycemia 
(both type 1 and type 2 DM). Among the sequelae of hyper-
glycemia, increased oxidative stress has captured consider-
able attention as a potential pathophysiological mechanism 
for cardiac dysfunction and HF in DM. An increase in the 
production of reactive oxygen species (ROS) in DM has 
been shown to result from the hyperglycemia-induced en-
hancement in glucose auto-oxidation, protein glycation (ad-
vanced glycation endproducts [AGEs]), and subsequent oxi-
dative degradation of glycated proteins [39-43]. Early ex-
perimental evidence implicating ROS in diabetic cardiac 
complications was mainly derived from reports evaluating 
the rate of lipid peroxidation. Increased cardiac levels of 
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peroxides were observed in rats treated with streptozotocin 
(STZ), a model of type 1 DM that mimics events observed in 
type 1 non-atherogenic diabetic cardiomyopathy [13, 14, 44]. 
However, these markers of lipid peroxidation were subse-
quently shown to lack specificity [45, 46]. Consequently, 
definitive evidence for the association of oxidative stress 
with diabetic heart disease from these studies was lacking. 
 F 2-isoprostanes, a novel class of prostaglandin F2-like 
compounds described by Roberts and Morrow [47], are 
formed in vivo by non-enzymatic free radical-catalyzed per-
oxidation of arachidonic acid [48, 49]. An important aspect 
of the discovery of isoprostanes is that measurement of F2-
isoprostanes has emerged as one of the most reliable ap-
proaches to assess oxidative stress status in vivo [49]. Of 
these, 8-iso-prostaglandin F2 (8-iso PGF2) has recentlybeen 
shown to be a specific and sensitive quantitative index of 
oxidative stress in vivo [50]. In that regard, we recently un-
dertook studies examining the myocardial formation of 8-iso 
PGF2 in type 1 DM complications involving the heart [51-
53]. We found that the levels of 8-iso PGF2 were signifi-
cantly higher in the surviving myocardium of diabetic post-
MI rats compared to the non-diabetic MI rats concomitant 
with an increased functional severity of HF [51]. In STZ rats 
with type 1 diabetic cardiomyopathy, left ventricular (LV) 
levels of 8-iso  PGF2 were significantly increased in vivo
[52, 53] which coincided with a specific ‘type 1 diabetic’ 
pattern of cardiac proteome changes [52]. Collectively, these 
experimental animal studies demonstrate that cardiac com-
plications of DM are associated with greater myocardial oxi-
dative stress burden. 
Clinical Studies 
  Increased levels of TBARS and lipid hydroperoxides 
have been observed in the plasma of both types of diabetic 
patients [54-57]. Consistent with the concept of enhanced 
lipid peroxidation, increased in vivo formation of F2-
isoprostanes such as 8-iso PGF2 have been documented to 
occur in the plasma and urine of diabetic patients [58, 59]. 
Elevated levels of PRFO products in diabetic patients have 
also been reported [60].  
  It has been reported that hyperglycemia increases nitric 
oxide (NO) and O2
- generation [61]. The reaction between 
NO and O2
-leads to inactivation of NO and production of the 
potent oxidant peroxynitrite (ONOO
-) [62]. In that regard, a 
study performed on patients with acute coronary syndrome 
undergoing coronary bypass surgery showed that diabetic 
ventricular biopsy specimens contained higher levels of O2
-
and nitrotyrosine during myocardial ischemia [63], indicat-
ing enhanced free radical-mediated oxidative stress damage. 
Moreover, there is evidence that in individuals with DM, 
nitrotyrosine levels are increased after MI [64], indicating 
elevated oxidative stress. Recently, it has been shown that 
both lipid hydroperoxides and protein nitrotyrosine markers 
of oxidative stress are increased to a greater extent in pa-
tients with DM than in those without DM who undergo 
coronary bypass grafting surgery for coronary artery disease 
[65]. Thus, these studies clearly demonstrate that cardiac 
complications in patients with DM are associated with a 
greater propensity for oxidative stress. 
CARDIOPROTECTIVE EFFECTS OF ANTIOXIDANT 
THERAPY ON THE DIABETIC HEART 
Evidence from Experimental Models 
Vitamin E 
  Natural vitamin E is a mixture of tocopherols and to-
cotrienols (-,  -,  -,  -tocopherol, and -,  -,  -,  -
tocotrienol), produced only by plants [66]. Of these, - toco-
pherol has the highest antioxidant potency [66]. Vitamin E is 
commercially available as either a mixture of naturally oc-
curring tocopherols and tocotrienols, synthetic - tocopherol 
(which consists of the eight possible stereoisomers in equal 
amounts), or a mixture of the synthetic tocopherol esters 
[67]. Its presence in biological membranes is thought to rep-
resent the major defense system against free-radical medi-
ated lipid peroxidation. 
Anti-Atherogenic Effects of Vitamin E 
  Supplementation with vitamin E to diabetic BALB/c 
mice, an experimental mouse model of atherosclerosis sec-
ondary to both hypercholesterolemia and hyperglycemia, 
was shown to retard coronary atherosclerosis accelerated by 
DM [68]. The beneficial effect of vitamin E observed in this 
model was demonstrated to be due to a reduction in oxida-
tive stress and not secondary to a decrease in plasma glucose 
or cholesterol, since their respective plasma concentrations 
remain unchanged in the diabetic mice supplemented with 
vitamin E [68]. Furthermore, it has been recently reported 
that macrophages from diabetic BALB/c mice are under ex-
cess oxidative stress and that the antioxidant vitamin E can 
attenuate macrophage oxidative stress which exists in DM 
and leads to accelerated atherosclerosis development [69]. 
Prophylactic Effects of Vitamin E Against HF in Diabetic 
Cardiomyopathy 
  We recently investigated whether dietary vitamin E sup-
plementation could confer cardioprotection against HF in 
type I diabetic cardiomyopathy. We found that supplementa-
tion of STZ-diabetic rats with 2000 IU of vitamin E/kg feed 
beginning immediately after induction of DM and continuing 
for 8 weeks provided significant protection against cardiac 
dysfunction induced by type 1 DM (Fig. 1 and Table 1) and 
that this cardioprotective effect was simultaneously associ-
ated with an ability of vitamin E to blunt diabetes-induced 
amplification of myocardial 8-iso PGF2 and GSSG forma-
tion [53]. These findings suggest the usefulness of vitamin E 
supplementation during the early phases of type 1 DM for 
the prophylaxis of cardiomyopathy and subsequent HF. 
Metallothionein 
  Metallothionein (MT) is a cysteine-rich protein that has 
the ability to bind metals such as zinc (Zn) and copper (Cu) 
[70, 71]. MT also functions as a potent antioxidant owing to 
its high thiol content [72]. MT has been reported to protect 
against oxidative DNA, protein, and lipid damage induced 
by various ROS and reactive nitrogen species (RNS) [70, 73-
75]. 
Metallothionein Prevents Diabetic Cardiomyopathy 
  Using a cardiac-specific, MT-overexpressing transgenic 
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nificantly diabetic cardiomyopathy and significantly sup-
press oxidative damage in the STZ-induced type 1 diabetic 
mouse model [76-78]. MT overexpression has also been re-
ported to be effective in reversing the diabetic deficit in 
whole-heart ischemic contractility seen in OVE26 diabetic 
mice, a genetically predisposed type 1 diabetic mouse model 
of diabetic cardiomyopathy [79]. Permanent antioxidant 
treatment by MT overexpression specifically in cardiomyo-
cytes has been demonstrated to be remarkably effective in 
ameliorating functional deficits in OVE26 diabetic cardio-
myocytes by inhibiting chronic ROS production [80], indi-
cating that ROS is essential to the pathogenesis of diabetic 
cardiomyopathy.  
  Zinc, the primary metal that binds to MT under physio-
logical conditions, is a potent inducer of MT [81, 82]. A re-
cent study examined whether Zn supplementation could pro-
tect against diabetic cardiomyopathy through cardiac MT 
induction [83]. The results from this study demonstrated that 
Zn supplementation to STZ-induced diabetic mice signifi-
cantly prevented the increases in cardiac morphological im-
pairment, fibrosis, and dysfunction observed in diabetic mice  
without Zn supplementation [83]. Zn supplementation to 
STZ-diabetic mice also induced a significant increase in car-
diac MT expression [83]. When MT expression was silenced 
with the use of MT small-interfering RNA in cultured myo-
cytes, the preventive effect of pretreatment with Zn was 
abolished [83]. These results provide evidence that the pre-
vention of diabetic cardiomyopathy by Zn supplementation 
is predominantly mediated by an increase in cardiac MT [83] 
and suggest Zn supplementation, with cardiac MT induction, 
as a potential therapeutic approach to prevent diabetic car-
diomyopathy.  
Resveratrol 
  Resveratrol, a polyphenolic phytoalexin compound, has 
been designated the principal effector constituent present in 
red wine [84]. Interest in this compound stems from reports 
that resveratrol exerts both vascular and cardioprotective 
effects in the non-diabetic setting [85, 86]. This beneficial 
effect has been attributed to the antioxidant activity of res-
veratrol. However, until recently, little or no data was avail- 
Fig. (1). Representative left ventricular (LV) pressure recordings and maximal rate of LV pressure rise and fall (±dP/dt) obtained from con-
trol and STZ-induced diabetic rats with and without vitamin E (Vit E) treatment: (A) control rat maintained on a basal, un-supplemented 
vitamin E (-Vit E) diet; (B) control rat maintained on a vitamin E-supplemented (+Vit E) diet; (C) STZ-diabetic rat maintained on a basal, 
un-supplemented vitamin E (-Vit E) diet; (D) STZ-diabetic rat maintained on a vitamin E-supplemented (+Vit E) diet. Reprinted from Ref. 
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able about the ability of the antioxidant resveratrol to protect 
the diabetic myocardium. In that regard, its therapeutic ef-
fects have now begun to be described in diabetes-induced 
cardiovascular complications. 
Resveratrol Alleviates Diabetic-Induced Post-Ischemic 
Cardiac Dysfunction 
  Das and colleagues have demonstrated a beneficial effect 
of resveratrol on diabetic ischemic reperfused myocardium 
using two different animal models of diabetes [87, 88]. Daily 
oral administration of resveratrol (2.5 mg/kg body wt/day) to 
STZ-induced diabetic rats for 15 consecutive days after 15 
days of STZ injection resulted in improved LV function fol-
lowing  ex-vivo ischemia-reperfusion [87]. Cardioprotection 
from ischemic injury in resveratrol-treated diabetic rats was 
demonstrated to occur via enhanced antioxidant activity and 
reduced blood glucose levels [87]. STZ-diabetic rats treated 
with resveratrol showed a marked increase in manganese 
(Mn) SOD activity after ischemia-reperfusion compared to 
the untreated STZ-diabetic rats [87]. Since it is well docu-
mented that hyperglycemia increases the production of ROS 
[39-43], the authors suggest that resveratrol-induced de-
crease of blood glucose in conjunction with increased 
MnSOD activity in diabetic rat myocardium may protect the 
diabetic heart from oxidative stress-induced cardiac dysfunc-
tion, even in the absence of ischemia/reperfusion [87].  
  Das and colleagues have also shown that pre-treatment 
with the antioxidant resveratrol improves the recovery of 
post-ischemic cardiac function in isolated hearts from Zucker 
obese diabetic rats [88], a model of dietary-induced insulin 
resistance that encompasses type 2 DM. The recovery of 
post-ischemic cardiac function was associated with a reduc-
tion in the incidence of reperfusion-induced ventricular fib-
rillation (VF) [88]. These results suggest that antioxidant 
treatment with resveratrol can improve post-ischemic cardiac 
dysfunction in the insulin-resistant diabetic state. 
Glutathione Peroxidase Synthetic Mimic BXT-51072 
  BXT-51072 is an orally bioavailable, catalytic mimic of 
GSHPx (Synvista Therapeutics, Inc.) [89, 90]. GSHPx, an 
important defense mechanism against not only myocardial
ischemia/reperfusion injury [91] but also post-MI cardiac
failure [92], has been reported to be markedly decreased in 
diabetic coronary heart disease patients [93].  
Infarct-Sparing Effects of BXT-Supplementation 
  Levy and colleagues have shown that oral administration 
of the antioxidant BXT-51072 at a dose of 5 mg/kg to DM 
mice homozygous for the haptoglobin 2 allele (Hp 2), which 
confers markedly less antioxidant protection against hemo-
globin-induced oxidation compared with the Hp 1 allele [94], 
reduces MI size after myocardial ischemia-reperfusion by 
more than 80% [95]. In addition, non-BXT-supplemented 
DM Hp 2 mice exhibited significantly greater amounts of 
myocardial lipid peroxidation products of arachidonic acid in 
association with increased MI size after ischemia-reperfusion 
[95]. These results suggest that decreasing oxidative stress 
with a GSHPx antioxidant mimic may prevent increased 
ischemia-reperfusion injury in the setting of DM.  
Tempol 
  Tempol is a membrane-permeable SOD mimetic that has 
been shown to attenuate the effects of peroxynitrite and ROS 
[96]. In DM, tempol has been shown to attenuate vascular 
complications [97, 98]. Until recently, the protective actions 
of this antioxidant against myocardial complications of dia-
betes remained unknown. 
Tempol Inhibits Cardiac Hypertrophy in the Pre-Diabetic 
Insulin-Resistant Heart 
  Insulin resistance is a characteristic feature of type 2 DM. 
The pre-diabetic insulin resistant heart exhibits many of the 
features of diabetic cardiomyopathy, including cardiac hy-
pertrophy [99, 100]. In vivo administration of the antioxidant 
tempol (1 mmol/l in drinking water) for a period of 4-weeks 
to mice rendered insulin-resistant by deficiency of the insu-
lin-sensitive GLUT4 transporter significantly and potently 
attenuated cardiac hypertrophy in concert with tempol up-
regulated ventricular expression of thioredoxin-2 (confirm-
ing an antioxidant action) [101]. Further studies are ongoing 
in an effort to determine to what extent functional benefit is 
conferred by this antioxidant intervention in the setting of 
insulin resistance.  
Table 1.  Effect of Vitamin E Supplementation on Left Ventricular Hemodynamic Parameters in Control and Diabetic Groups of 
Animals 
Parameter   Control - Vit E   Control + Vit E  Diabetes - Vit E  Diabetes + Vit E 
LVSP (mm Hg)  129.2 ± 0.9  128.2 ± 3.6  99.6 ± 2.3
 111.5  ± 2.0

LVEDP (mm Hg)  0.6 ± 0.5  0.8 ± 0.7  5.1 ± 0.7
 2.8  ± 0.6

+dP/dt (mm Hg/s)  8379 ± 98  8136 ± 140  5103 ± 241
 5965  ± 254

-dP/dt (mm Hg/s)  7552 ± 287  8024 ± 224  4071 ± 134
 4700  ± 265

Heart Rate (bpm)  308 ± 6.0  321 ± 4.6   208 ± 9.8
 206  ± 4.6

MAP (mm Hg)  114.7 ± 3.1   115.8 ± 5.1  87.3 ± 2.9
 101.7  ± 3.4

Values are mean ± SEM of 6-8 animals. 
Significantly different (P<0.05) from control groups with vitamin E 
(+Vit E) and without vitamin E (-Vit E) supplementation. 
Significantly different (P<0.05) from the un-supplemented  
diabetic group. Reprinted from Ref. 53 (Copyright 2007), with permission from Elsevier. 264 Current Cardiology Reviews, 2008, Vol. 4, No. 4 Michael F. Hill 
EVIDENCE FROM CLINICAL TRIALS 
Vitamin E 
Vitamin E Supplementation Reduces MI 
  The Secondary Prevention with Antioxidants of Cardio-
vascular Disease in End Stage Renal Disease (SPACE) trial 
[19] investigated the effect of high-dose vitamin E supple-
mentation on cardiovascular disease outcomes in hemodialy-
sis patients with pre-existing cardiovascular disease. In this 
trial, 196 hemodialysis patients with pre-existing cardiovas-
cular disease were randomized to receive 800 IU/day vitamin 
E (n=97) or matching placebo (n=99) for 2 years. 42% of the 
patients in the placebo group had diabetes while 43% of the 
patients in the vitamin E group had diabetes. The primary 
endpoint was a composite variable consisting of: MI (fatal 
and non-fatal), ischemic stroke, peripheral vascular disease, 
and unstable angina [19]. A 46% reduction in composite 
cardiovascular disease endpoints in the hemodialysis patients 
treated with high-dose vitamin E during the 2 years’ follow-
up was observed and this was largely due to a 70% reduction 
in total MI [19]. In that regard, evaluation of serum antioxi-
dants in participants identified from the Pittsburgh Epidemi-
ology of Diabetes Complications Study (EDC) cohort, a 10-
year prospective follow-up study of childhood–onset (<17 
years of age) type I DM patients, revealed that high serum -
tocopherol levels among type 1 DM patients with overt 
nephropathy were associated with a significantly lower coro-
nary artery disease (CAD) incidence (as determined by EDC 
physician-diagnosed angina or MI confirmed by Q-waves on 
electrocardiogram) during the follow-up period in type I dia-
betes [102]. This cardioprotective effect of -tocopherol 
among individuals with renal disease in type I DM was inde-
pendent of traditional cardiovascular disease risk factors, or 
other serum antioxidants [102]. 
  The marked increase in lipid peroxidation products of 
arachidonic acid in the myocardium of DM Hp 2 mice occur-
ring after myocardial ischemia-reperfusion [95] prompted 
Levy and colleagues to investigate whether antioxidant ther-
apy with vitamin E might have reduced cardiovascular 
events in Hp 2-2 DM patients that participated in the HOPE 
(Heart Outcomes Prevention Evaluation) trial (23). Hp geno-
type was assessed in stored blood samples from HOPE. 
Analysis of this HOPE cohort showed that vitamin E treat-
ment significantly reduced MI and cardiovascular death by 
43% and 55%, respectively, in these Hp 2-2 DM individuals 
[103]. However, due to the retrospective nature of this analy-
sis, Levy and colleagues sought to test the validity of these 
findings in Hp 2-2 DM patients in a prospective, double-
blind, placebo controlled clinical trial of vitamin E [104]. 
1434 DM patients with the Hp 2-2 genotype were random-
ized to vitamin E (400 U/day) or placebo [104]. At the first 
interim analysis, 18 months after initiating the study, cardio-
vascular events were found to be significantly reduced in the 
cohort of Hp 2-2 DM patients receiving vitamin E compared 
with placebo (Fig. 2), which led to an early termination of 
the study [104]. The reduction in cardiovascular events in the 
vitamin E-treated group of patients was in large part attribut-
able to a significant reduction in the incidence of non-fatal 
MI [104]. These results suggest that this subgroup of DM 
patients, in particular, may derive cardiovascular benefit 
from treatment with the antioxidant vitamin E and in addi-
tion, provide further affirmation of the ability of vitamin E to 
reduce MI in the diabetic population. 
  The observed benefit with vitamin E in the above men-
tioned ongoing clinical studies are incongruent with the re-
sults from the most recent randomized placebo-controlled 
clinical trials [22-26]. In fact, in these trials it was very clear 
that vitamin E supplementation had little impact on the de-
velopment of atherosclerosis in all comers, including diabet-
ics. However, in the majority of these studies, the partici-
pants were older individuals (> 55 years of age) with ad-
vanced disease. To that end, study patients that participated 
in the HOPE trial [23] had preexisting coronary or peripheral 
artery disease, stroke, or DM in the presence of at least one 
additional cardiovascular disease risk factor, and the mean 
age was 66 years. In the GISSI-Prevenzione trial [22], study 
participants were exclusively patients who had survived MI 
and included older patients (30% of the patients randomly 
allocated to receive vitamin E treatment were in the 51-60 
years of age category while 33% of the patients randomly 
allocated to receive vitamin E treatment were in the 61-70 
years of age category). As a result, it is possible that the 
study populations in these most recent randomized placebo-
controlled clinical trials represented patients in whom the 
Fig. (2). Kaplan-Meier plot of the composite end point in Hp 2-2 
DM individuals allocated to vitamin E or placebo. Events are CV 
death, myocardial infarction, or stroke. There were 726 Hp 2-2 
individuals allocated to vitamin E and 708 Hp 2-2 individuals allo-
cated to placebo. As a reflection of the 18-month window during 
which participants entered the study (time 0 being the day of Hp 
typing) and the early termination of the study not all participants 
were in the study for the same duration. This is reflected in the 
abscissa where the number of individuals in the study (the number 
at risk) for a given duration is provided. There were a total of 16 
patients (2.2%) who had events in the vitamin E group and 33 pa-
tients who had events in the placebo group (4.7%). There was a 
significant decrease in the composite end point in the vitamin E 
group compared with the placebo group (HR 0.47 [95% CI 0.27 to 
0.82], P=0.01 by log-rank). Reprinted from Ref. 104 (Copyright 
2008), with permission from the American Heart Association, Inc. 
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coronary artery lesions were too far advanced to be amenable 
to antioxidant intervention with vitamin E. 
Resveratrol (Red Wine) 
Moderate Red Wine Intake Improves Cardiac Function 
After MI 
  The preclinical observations that resveratrol treatment 
can improve post-ischemic cardiac dysfunction in the setting 
of DM [87, 88] by favorably altering oxidative stress [87] 
have also been demonstrated in diabetic MI patients. Mar-
fella et al. examined the effects of moderate red wine intake 
on oxidative stress and echocardiographic parameters of 
functional cardiac outcome in DM patients after a first un-
complicated MI [105]. One hundred and fifteen subjects with 
DM who had sustained a first and recent (< 2 months) non-
fatal MI were randomized to receive either one 118 ml (4-oz) 
glass of wine each day or no red wine (control group) for a 
period of 1 year [105]. After the 1 year intervention period, 
circulating levels of nitrotyrosine were significantly reduced 
in the diabetic MI patients receiving red wine compared to 
the diabetic MI patients that did not intake red wine [105]. In 
addition, moderate red wine intake among the diabetic MI 
subjects resulted in a significantly higher ejection fraction 
and significant improvement of dys-synchrony between right 
and left ventricular contraction and relaxation as compared 
to the diabetic MI patients who did not receive red wine 
[105]. These clinical data suggest that red wine consumption, 
in moderate amounts, may be an effective antioxidant ther-
apy for preventing oxidant-dependent complications of MI in 
DM patients [106]. 
FUTURE DIRECTIONS 
  Efforts are underway to achieve successful delivery of 
antioxidants specifically in the diabetic heart in order to 
maximize the potential roles of antioxidants in prophylaxis 
and therapy of cardiac complications of DM. The experimen-
tal results by Epstein and colleagues demonstrating that car-
diac-overexpression of antioxidant transgenes permanently 
and specifically in hearts of type 1 and type 2 diabetic mice 
can prevent and reverse diabetes-induced defects in cardio-
myocytes attributable to ROS production [80, 107, 108] sug-
gests that gene therapy of antioxidants may evolve into po-
tential approaches for the treatment of diabetic heart diseases 
related to oxidative stress. However, its clinical application 
must await the advent of effective and safe gene delivery 
methods.
CONCLUSIONS 
  While both the American Heart Association and the 
American Diabetes Association remain jointly committed to 
preventing DM [109, 110], the explosive gain in the preva-
lence of obesity in adolescents over the past three decades 
increases the likelihood that the number of people with diag-
nosed DM will continue to soar in the near term. Because 
cardiovascular disease is the major cause of morbidity and 
mortality for individuals with DM, emphasis on treatment 
strategies aimed at reducing cardiac complications secondary 
to DM are essential for improving the poor outcome of these 
patients. In that regard, the recent emergence of evidence 
demonstrating the efficacy of antioxidants as prophylactic 
and therapeutic agents for cardiac complications of DM sup-
port a role for antioxidant therapy in protecting against car-
diovascular disease inflicted by accentuated oxidative stress 
intrinsic to the diabetic state. An important consideration 
regarding antioxidant therapeutic strategies is the measure-
ment of biomarkers of oxidative stress [111]. Implicit in the 
majority of randomized placebo-controlled clinical trials that 
have previously explored the benefits of antioxidant supple-
mentation in preventing cardiovascular events is that the 
antioxidants tested effectively suppressed oxidative stress 
status but this was never determined [112]. The omission of 
oxidative stress monitoring and consequent absence of data 
demonstrating suppression in the levels of oxidative stress in 
relation to the dose of antioxidants tested in the study par-
ticipants enrolled in these trials could explain the null results 
in certain studies. Moreover, evidence of increased oxidative 
stress was not a criterion for inclusion in these clinical trials; 
therefore, antioxidants may have benefited only a subset of 
the participants [111]. The demonstration that antioxidants 
such as vitamin E and resveratrol do in fact significantly 
suppress F2-isoprostanes and nitrotyrosine (oxidative stress 
biomarkers) in both humans and animals with increased oxi-
dative stress associated with diabetic cardiovascular diseases 
may be especially important for the diabetic myocardium, 
owing to its greater propensity for oxidative stress that leads 
to the development of HF [51]. In addition, this information 
could inform future studies evaluating the effects of antioxi-
dants in diabetic cardiac disease states associated with oxida-
tive stress about appropriate doses to evaluate treatment re-
quired for a significant effect in this population cohort. Ad-
ministration of antioxidant supplements beginning early after 
the diagnosis of DM merits serious consideration as an addi-
tional therapeutic modality to be incorporated into the thera-
peutic armamentarium to reduce the risk of future cardiovas-
cular complications. 
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